Literature DB >> 30091851

Isolation of Antibodies to Heparan Sulfate on Glypicans by Phage Display.

Heungnam Kim1, Mitchell Ho1.   

Abstract

Heparan sulfate (HS) plays an important role in development and disease. It interacts with many growth factors, chemokines, and other ligands known to be important for cell growth, motility, and differentiation. However, isolating an antibody to HS in mice, rabbits, or humans is difficult due to the poor immunogenicity of HS. Phage display is a major antibody engineering technology that allows the selection of antibodies for poorly immunogenic or highly conserved antigens. This protocol contains detailed procedures for HS antigen preparation and isolation of a phage displayed human single-chain Fv (HS20) that binds HS on glypican-3 (GPC3), and analysis of the selected phage antibody. It is conceivable that the procedures described in this protocol may be applicable to the isolation of antibodies for a variety of HS molecules.
© 2018 by John Wiley & Sons, Inc. © 2018 John Wiley & Sons, Inc.

Entities:  

Keywords:  glypican; heparan sulfate proteoglycan; phage display; single-chain variable fragment or scFv

Mesh:

Substances:

Year:  2018        PMID: 30091851      PMCID: PMC6205898          DOI: 10.1002/cpps.66

Source DB:  PubMed          Journal:  Curr Protoc Protein Sci        ISSN: 1934-3655


  10 in total

1.  The hybridoma revolution: an offshoot of basic research.

Authors:  C Milstein
Journal:  Bioessays       Date:  1999-11       Impact factor: 4.345

Review 2.  High-throughput screening of surface displayed gene products.

Authors:  G Walter; Z Konthur; H Lehrach
Journal:  Comb Chem High Throughput Screen       Date:  2001-04       Impact factor: 1.339

3.  Site-specific anti-C3a receptor single-chain antibodies selected by differential panning on cellulose sheets.

Authors:  H Hawlisch; M Müller; R Frank; W Bautsch; A Klos; J Köhl
Journal:  Anal Biochem       Date:  2001-06-01       Impact factor: 3.365

4.  Antibody arrays for high-throughput screening of antibody-antigen interactions.

Authors:  R M de Wildt; C R Mundy; B D Gorick; I M Tomlinson
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

5.  Phage antibodies: filamentous phage displaying antibody variable domains.

Authors:  J McCafferty; A D Griffiths; G Winter; D J Chiswell
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

6.  Selection of human antibody fragments by phage display.

Authors:  Carol M Y Lee; Niccolo Iorno; Frederic Sierro; Daniel Christ
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

7.  Magnetic bead enzyme-linked immunosorbent assay (ELISA) detects antigen-specific binding by phage-displayed scFv antibodies that are not detected with conventional ELISA.

Authors:  M Kala; K Bajaj; S Sinha
Journal:  Anal Biochem       Date:  1997-12-15       Impact factor: 3.365

Review 8.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

9.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.

Authors:  G P Smith
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

10.  Chromato-panning: an efficient new mode of identifying suitable ligands from phage display libraries.

Authors:  Wim Noppe; Fatima Plieva; Igor Yu Galaev; Hans Pottel; Hans Deckmyn; Bo Mattiasson
Journal:  BMC Biotechnol       Date:  2009-03-17       Impact factor: 2.563

  10 in total
  6 in total

1.  Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display.

Authors:  Ruonan Feng; Ruixue Wang; Jessica Hong; Christopher M Dower; Brad St Croix; Mitchell Ho
Journal:  Antib Ther       Date:  2020-02-17

Review 2.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 3.  Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.

Authors:  Bryan D Fleming; Mitchell Ho
Journal:  Biomolecules       Date:  2020-06-20

Review 4.  Perspectives on the development of neutralizing antibodies against SARS-CoV-2.

Authors:  Mitchell Ho
Journal:  Antib Ther       Date:  2020-05-20

Review 5.  Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.

Authors:  Yaping Sun; Mitchell Ho
Journal:  Antib Ther       Date:  2020-11-24

6.  Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.

Authors:  Jessica Hong; Hyung Joon Kwon; Raul Cachau; Catherine Z Chen; Kevin John Butay; Zhijian Duan; Dan Li; Hua Ren; Tianyuzhou Liang; Jianghai Zhu; Venkata P Dandey; Negin P Martin; Dominic Esposito; Uriel Ortega-Rodriguez; Miao Xu; Mario J Borgnia; Hang Xie; Mitchell Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-27       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.